Tesamorelin the science.

Tesamorelin (sometimes referenced by the research code TH9507) is a synthetic 44-amino-acid peptide based on human GHRH, modified with an N-terminal group that improves its stability. Because it acts upstream — on the pituitary’s own GHRH receptor — it is studied as a way to raise growth hormone and IGF-1 through the body’s endogenous, pulsatile release rather than by administering growth hormone directly.

As a prescription medicine, tesamorelin is approved by the U.S. FDA for the reduction of excess abdominal fat (visceral adipose tissue) in people with HIV-associated lipodystrophy. The compound discussed on this page is supplied strictly as a research material and is not the approved pharmaceutical product.

Tesamorelin research is organized around the somatotropic axis:

• GHRH receptor — tesamorelin binds the pituitary GHRH receptor, stimulating release of stored growth hormone.
• Pulsatile GH release — because it works upstream, studies examine how it preserves the natural pulsing pattern of GH secretion.
• IGF-1 signaling — downstream, GH drives hepatic IGF-1 production, the mediator examined in metabolic and body-composition endpoints.

Tesamorelin has an extensive human clinical literature in addition to preclinical pharmacology:

• Visceral-fat trials. Randomized, placebo-controlled studies in adults with HIV-associated lipodystrophy reported reductions in visceral adipose tissue over treatment periods of roughly 6–12 months.
• Metabolic-profile analyses. Published analyses examined how reductions in visceral adiposity related to lipid and metabolic markers, and identified predictors of response.

These findings come from trials of the medicine in a defined clinical population. They are reported here as research context and do not represent claims about the research material supplied on this page.

Tesamorelin is supported by published human clinical-trial data and is approved as a prescription medicine for a specific indication. That approval applies to the pharmaceutical product under medical supervision — not to research material. The compound supplied here is for research use only, not for human or veterinary use, and no dosing or therapeutic claim is made about it.